Kimia Biosciences Limited has successfully concluded its postal ballot process for the reappointment of Mr. Sameer Goel as Managing Director, with shareholders demonstrating overwhelming support for the resolution. The company announced the voting results on March 23, 2026, in compliance with SEBI regulations.

Voting Results and Shareholder Participation

The postal ballot achieved significant shareholder participation with comprehensive voting across different categories. The company had 12,783 total shareholders on the record date of February 06, 2026.

Resolution Details and Approval

The ordinary resolution for approving the reappointment of Mr. Sameer Goel as Managing Director received exceptional support from shareholders. The final voting summary showed remarkable consensus among participants.

Postal Ballot Process and Timeline

The company conducted the postal ballot process entirely through e-voting in accordance with regulatory requirements. Key process milestones included:

• Record Date: February 06, 2026
• Scrutinizer Appointment: February 14, 2026
• Notice Date: February 16, 2026
• Notice Dispatch: February 18, 2026 (to 3,619 members via email)
• Advertisement Publication: February 19, 2026 in Financial Express (English) and Jansatta (Hindi)
• Voting Period: February 20, 2026 (9:00 AM IST) to March 21, 2026 (5:00 PM IST)
• Results Declaration: March 23, 2026

Scrutinizer's Certification

CS Maghisuddin from M & CO. Company Secretaries served as the appointed scrutinizer for the postal ballot process. The scrutinizer confirmed that all votes cast by members were found to be valid after thorough examination. The report verified that the ordinary resolution was passed with the requisite majority as per statutory requirements.

Regulatory Compliance

The postal ballot was conducted in full compliance with Section 110 of the Companies Act, 2013, and the Companies (Management and Administration) Rules, 2014. The process also adhered to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with results being made available on the company's website and submitted to BSE Limited.

The successful completion of this postal ballot process demonstrates strong shareholder confidence in the company's leadership under Mr. Sameer Goel's continued guidance as Managing Director.

Kimia biosciences Limited has announced the resignation of Mr. Kaku Vijaya Shekhar Reddy from his position as Additional Director in the category of Executive Director. The pharmaceutical company informed BSE Limited about this corporate governance change through a regulatory filing dated February 19, 2026.

Director Resignation Details

The resignation became effective from February 18, 2026, with the company accepting it from the closure of business hours on February 19, 2026. Mr. Reddy cited personal reasons for his departure from the executive position.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Pallavi Garg signed the regulatory filing, ensuring compliance with disclosure requirements under SEBI Master Circular No. SEBI/HO/CFD/PoD2/ClR/P/0155 dated November 11, 2024.

Director's Service Tenure

According to the resignation letter, Mr. Reddy had been serving as Director Technical since December 5, 2025. In his resignation communication addressed to Managing Director Mr. Sameer Gool, he mentioned that unforeseen personal circumstances necessitated stepping away from his professional responsibilities. He requested immediate release from his duties while expressing gratitude for the opportunity to serve the pharmaceutical company.

Company Information

Kimia Biosciences Limited operates from its registered office and works located at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana. The company also maintains a corporate office at Aggarwal Millennium Tower-II in New Delhi's Netaji Subhash Place, Pitampura.